Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

39.52 +0.25 (+0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 548,901
Open 39.34
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 39.27
Today's Range 39.05 - 39.64
52wk Range 31.19 - 44.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React
The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi. 
Via Stocktwits
Topics Government
Exposures Political

Performance

YTD
+13.1%
+13.1%
1 Month
-2.4%
-2.4%
3 Month
-4.8%
-4.8%
6 Month
+11.0%
+11.0%
1 Year
+26.3%
+26.3%

More News

Read More
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
From Genentech
Via Business Wire
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
From Genentech
Via Business Wire
The Smartest Vanguard ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Via Investor's Business Daily
Exposures Product Safety
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Via Benzinga
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Via Benzinga
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
Via Benzinga
Exposures Product Safety
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government
Exposures Political
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%
Via Benzinga
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
From Genentech
Via Business Wire
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Roche and Genentech Announce New North Carolina Manufacturing Facility
From Genentech
Via Business Wire
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
Via Benzinga
Topics Government
Exposures Political
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Via The Motley Fool
Topics Earnings Government World Trade
Exposures Financial Political Tariff
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low
Via Investor's Business Daily
Topics Death
Exposures Death Product Safety
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
Via Benzinga
Exposures Product Safety
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Via MarketBeat
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Political
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
From Genentech
Via Business Wire
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
Via Investor's Business Daily
Topics Earnings Government
Exposures Financial Political
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Via Benzinga

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 39.52
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 05/29/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.